This Project Grant award of $2,683,965 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support the development and optimization of an improved all-human cellular system, or "brain-chip", for studying Alzheimer's disease and related dementias (ADRDs). The key objectives are to: 1) define delivery conditions for introducing patient blood cells and plasma into...
This $3.6 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research at the Icahn School of Medicine at Mount Sinai directed at understanding the role of glial cell interactions surrounding amyloid plaques in the progression of Alzheimer's disease. As part of the Aging Research program (CFDA 93.866), the three-year award will support investigation of how deletion of the Plexin-B1 gene impacts glial network formation and the...
The National Institute on Aging (NIA), part of the National Institutes of Health within the Department of Health and Human Services, awarded a $2,567,371 Project Grant to The Trustees of Columbia University in the City of New York under the Aging Research program (CFDA 93.866). The grant will fund research from May 1, 2022 to April 30, 2025 to identify cell type-specific autonomous and non-autonomous interactions in Alzheimer's disease (AD) using induced pluripotent stem cell (iPSC) lines from...
This Cooperative Agreement award of $763,225 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to identify gene-environment interactions (GxE) that contribute to the risk of Alzheimer's disease (AD). The project will use an in vitro "GxE in a dish" model with 100 induced pluripotent stem cell (iPSC) donors to assess the context-specific function of common genetic variants. Researchers will expose cortical organoids derived from these iPSCs to...
The National Institutes of Health's National Institute on Aging awarded a $7,432,562 project grant to the Regents of the University of California, San Francisco on September 15, 2022 under the Aging Research program (CFDA 93.866). The grant will support research to elucidate the roles of Alzheimer's disease risk genes and variants in gene expression and AD-related phenotypes through 2025. Specifically, the University of California, San Francisco will use CRISPR and single-cell RNA sequencing...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
The National Institute on Aging awarded a $1,931,965 Project Grant (CFDA 93.866 - Aging Research) to the Regenerative Research Foundation, a non-profit organization in Albany, New York. The purpose of this federal grant is to develop and validate a novel human induced pluripotent stem cell (iPSC) model that incorporates cerebral cortical neurons, glia, vascular endothelial cells, and microglia to study cerebrovascular interactions in Alzheimer's disease-related dementias (ADRD). The R61 phase of...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $454,271 to Florida Atlantic University to investigate the role of amyloid precursor protein (APP) and cholesterol homeostasis in synaptic dysfunction and neurodegeneration related to Alzheimer's disease (AD). The research aims to use human neurons derived from induced pluripotent stem cells (hiNs) to systematically study how mutations affecting APP distribution, trafficking, and interaction...
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $3,845,311 to the University of California, San Diego (UCSD) to investigate the early determinants of Alzheimer's disease (AD) using age-equivalent neurons derived from mild cognitive impairment (MCI) patients. The project aims to better understand the convergence of risk factors, including polygenic variants and biological aging, on molecular pathways that initiate and...
The National Institute on Aging (NIA) awarded a $619,681 Project Grant (CFDA 93.866 - Aging Research) to The Leland Stanford Junior University (Stanford University) to develop innovative tools for studying the complex genetic interactions underlying Alzheimer's disease (AD) pathogenesis. The project, titled "Combinatorial Perturbation with Multi-Omics Readout to Dissect Etiology of Alzheimer's Disease Using Stem Cell and In Vivo Models", will create a toolkit combining gene-editing...
GENETICS-INFORMED DISSECTION OF HUMAN BRAIN CELL-CELL COMMUNICATION IN ALZHEIMER'S DISEASE PROGRESSION - ABSTRACT AD IS AN AGE-RELATED NEURODEGENERATIVE DISEASE AND THE LEADING CAUSE OF DEMENTIA IN THE UNITED STATES. IT IS CHARACTERIZED BY A PROGRESSIVE DECLINE OF MEMORY AND COGNITIVE IMPAIRMENT, ULTIMATELY LEADING TO DEMENTIA. CURRENTLY, MORE THAN 5.7 MILLION AMERICANS ARE AFFECTED BY AD, AND THIS NUMBER IS PROJECTED TO BE 16 MILLION BY 2050. ALTHOUGH A TREMENDOUS EFFORT HAS BEEN DEVOTED TO AD RESEARCH, THERE ARE NO EFFECTIVE DISEASE MODIFYING DRUGS AVAILABLE FOR AD, LARGELY DUE TO THE LACK OF UNDERSTANDING OF THE COMPLEX ETIOLOGY OF AD. ALTHOUGH THE ULTIMATE DAMAGE IN AD BRAIN IS NEURONAL LOSS, MULTIPLE CELL TYPES IN BRAIN ARE INVOLVED IN AD DEVELOPMENT AND PROGRESSION. GLIA CELLS, E.G. MICROGLIA AND ASTROCYTES, ARE CRUCIAL FOR BRAIN HEALTHY BRAIN. OTHER CELL TYPES, E.G. VASCULATURE CELLS INCLUDING PERICYTES AND ENDOTHELIA CELLS, THE MAJOR COMPONENTS OF BRAIN-BLOOD BARRIER, AND OLIGODENDROCYTES, WHICH IS RESPONSIBLE FOR MYELINATION OF AXONS, ARE ALL IMPLICATED IN AD. HOW THESE KEY CELL TYPES INTERACT DURING AD DEVELOPMENT, AND IN PARTICULAR HOW GLIA CELLS, E.G. MICROGLIA AND ASTROCYTES, INTERACT WITH NEURONS TO LEAD TO NEURONAL DEATH, ARE POORLY UNDERSTOOD. IN THIS APPLICATION, WE PROPOSE TO DEVELOP NOVEL ANALYTIC APPROACHES TO DISSECT CELL- CELL COMMUNICATION (CCC) AMONG MICROGLIA, ASTROCYTES AND NEURONS, AND HOW THE COMMUNICATIONS ARE DYSREGULATED DURING AD PROGRESSION, AND VALIDATE THE CANDIDATE CCC IN HUMAN IPSC-DERIVED CORTICAL ORGANOIDS. SPECIFICALLY, WE WILL DEVELOP NOVEL NETWORK-BASED MODELS AND STATISTICAL METHODS TO IDENTIFY CCC LINKED TO AD PATHOGENESIS (AIM 1), APPLY THE DEVELOPED METHODS TO ANALYZE PUBLIC SINGLE CELL -OMICS DATA TO IDENTIFY CCC LINKED TO AD PATHOLOGY AND COGNITIVE FUNCTION (AIM 2), AND VALIDATE THE CANDIDATE CCC IN HUMAN IPSC-DERIVED CORTICAL ORGANOIDS TO DECIPHER THE MULTI-CELLULAR COMMUNICATIONS UNDERLYING AD DEVELOPMENT (AIM 3).